Skip to content
2000
Volume 21, Issue 5
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

Pleural malignancy is an aggressive malignancy of the pleural surface and is primarily associated with asbestos exposure. Malignant pleural mesothelioma (MPM) is an invasive form of mesothelioma and resistant to conventional therapy. Recently, it has also been reported that carbon nanotube (CNTs) exposure can induce inflammation and fibrosis of the pleura and induce tumor development pre-clinical model. Although several strategies like immunotherapy (Dendritic cells, immune checkpoint inhibitors, CAR-T cell therapy), and viral therapy are being employed for the management of MPM. However, poor prognosis and limited treatment options make the problem worse. Apart from clinical challenges, industrial and socioeconomic challenges are key factors for the patients as they are mainly industry workers or their associates. This article is focused on industrial, clinical and socioeconomic challenges associated with malignant pleural mesothelioma (MPM) patients and available opportunities.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cctr/10.2174/0115733947315242240718074626
2024-07-23
2026-02-14

  • From This Site

    /content/journals/cctr/10.2174/0115733947315242240718074626
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BibbyA.C. TsimS. KanellakisN. BallH. TalbotD.C. BlythK.G. MaskellN.A. PsallidasI. Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment.Eur. Respir. Rev.20162514247248610.1183/16000617.0063‑201627903668
     [Google Scholar]
  2. UrsoL. CavallariI. SharovaE. CiccareseF. PaselloG. CiminaleV. Metabolic rewiring and redox alterations in malignant pleural mesothelioma.Br. J. Cancer20201221526110.1038/s41416‑019‑0661‑931819191
     [Google Scholar]
  3. PiraE. DonatoF. MaidaL. DiscalziG. Exposure to asbestos: past, present and future.J. Thorac. Dis.201810S2Suppl. 2S237S24510.21037/jtd.2017.10.12629507791
     [Google Scholar]
  4. MatsuzakiH. MaedaM. LeeS. NishimuraY. Kumagai-TakeiN. HayashiH. YamamotoS. HatayamaT. KojimaY. TabataR. Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis.J Biomed Biotechnol2012201249260810.1155/2012/492608
     [Google Scholar]
  5. TedescoJ. JaradehM. VigneswaranW.T. Malignant pleural mesothelioma: Current understanding of the immune microenvironment and treatments of a rare disease.Cancers20221418441510.3390/cancers1418441536139575
     [Google Scholar]
  6. LandriganP.J. LioyP.J. ThurstonG. BerkowitzG. ChenL.C. ChillrudS.N. GavettS.H. GeorgopoulosP.G. GeyhA.S. LevinS. PereraF. RappaportS.M. SmallC. Health and environmental consequences of the world trade center disaster.Environ. Health Perspect.2004112673173910.1289/ehp.670215121517
     [Google Scholar]
  7. KampD.W. GraceffaP. PryorW.A. WeitzmanS.A. The role of free radicals in asbestos-induced diseases.Free Radic. Biol. Med.199212429331510.1016/0891‑5849(92)90117‑Y1577332
     [Google Scholar]
  8. TanakaS. ChoeN. HemenwayD.R. ZhuS. MatalonS. KaganE. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat.J. Clin. Invest.1998102244545410.1172/JCI31699664087
     [Google Scholar]
  9. PandeyS.K. Machlof-CohenR. SanthanamM. Shteinfer-KuzmineA. Shoshan-BarmatzV. Silencing vdac1 to treat mesothelioma cancer: Tumor reprograming and altering tumor hallmarks.Biomolecules202212789510.3390/biom1207089535883451
     [Google Scholar]
  10. FuruyaS. Chimed-OchirO. TakahashiK. DavidA. TakalaJ. Global asbestos disaster.Int. J. Environ. Res. Public Health2018155100010.3390/ijerph1505100029772681
     [Google Scholar]
  11. FrankA.L. JoshiT.K. The global spread of asbestos.Ann. Glob. Health201480425726210.1016/j.aogh.2014.09.01625459326
     [Google Scholar]
  12. HughesJ.M. WeillH. Asbestos exposure--quantitative assessment of risk.Am. Rev. Respir. Dis.1986133151310.1164/arrd.1986.133.1.53510581
     [Google Scholar]
  13. PaustenbachD. BrewD. LigasS. HeywoodJ. A critical review of the 2020 EPA risk assessment for chrysotile and its many shortcomings.Crit. Rev. Toxicol.202151650953910.1080/10408444.2021.196833734651555
     [Google Scholar]
  14. StaynerL. WelchL.S. LemenR. The worldwide pandemic of asbestos-related diseases.Annu. Rev. Public Health201334120521610.1146/annurev‑publhealth‑031811‑12470423297667
     [Google Scholar]
  15. WilliamsP.R.D. PhelkaA.D. PaustenbachD.J. A review of historical exposures to asbestos among skilled craftsmen (1940-2006).J. Toxicol. Environ. Health B Crit. Rev.200710531937710.1080/1093740060103419117687724
     [Google Scholar]
  16. CowanD.M. ChengT.J. GroundM. SahmelJ. VarugheseA. MadlA.K. Analysis of workplace compliance measurements of asbestos by the U.S. Occupational Safety and Health Administration (1984–2011).Regul. Toxicol. Pharmacol.201572361562910.1016/j.yrtph.2015.05.00225985714
     [Google Scholar]
  17. U.S. Environmental Protection Agency.Available from: https://www.epa.gov/
  18. LinR.T. ChienL.C. JimbaM. FuruyaS. TakahashiK. Implementation of national policies for a total asbestos ban: A global comparison.Lancet Planet. Health201938e341e34810.1016/S2542‑5196(19)30109‑331439315
     [Google Scholar]
  19. AlgrantiE. SantanaV.S. CamposF. SalviL. SaitoC.A. CavalcanteF. Correa-FilhoH.R. Analysis of mortality from asbestos-related diseases in brazil using multiple health information systems, 1996-2017.Saf. Health Work202213330230710.1016/j.shaw.2022.04.00636156859
     [Google Scholar]
  20. MuralidharV. RaghavP. DasP. GoelA. A case from India of pleural malignant mesothelioma probably due to domestic and environmental asbestos exposure: A posthumous report.BMJ Case Rep.2019123e22788210.1136/bcr‑2018‑22788230936339
     [Google Scholar]
  21. JoshiT.K. BhuvaU.B. KatochP. Asbestos Ban in India.Ann. N. Y. Acad. Sci.20061076129230810.1196/annals.1371.07217119210
     [Google Scholar]
  22. BroeckxG. PauwelsP. Malignant peritoneal mesothelioma: A review.Transl. Lung Cancer Res.20187553754210.21037/tlcr.2018.10.0430450291
     [Google Scholar]
  23. Ismail-KhanR. RobinsonL.A. WilliamsC.C.Jr GarrettC.R. BeplerG. SimonG.R. Malignant pleural mesothelioma: A comprehensive review.Cancer Contr.200613425526310.1177/10732748060130040217075562
     [Google Scholar]
  24. KondolaS. MannersD. NowakA.K. Malignant pleural mesothelioma: An update on diagnosis and treatment options.Ther. Adv. Respir. Dis.201610327528810.1177/175346581662880026873306
     [Google Scholar]
  25. BorgeaudM. KimF. FriedlaenderA. LococoF. AddeoA. MinerviniF. The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma.J. Clin. Med.2023125175710.3390/jcm1205175736902544
     [Google Scholar]
  26. KoršaL. LukačA. KovačevićL. BilićI. PrutkiM. MarušićZ. Breast metastasis as the initial presentation of malignant pleural mesothelioma.Breast J.202026102063206410.1111/tbj.1389832475021
     [Google Scholar]
  27. RajaS. MurthyS.C. MasonD.P. Malignant pleural mesothelioma.Curr. Oncol. Rep.201113425926410.1007/s11912‑011‑0177‑921573909
     [Google Scholar]
  28. CholletB. GuindeJ. LaroumagneS. DutauH. AstoulP. Does the LENT score risk-stratify patients with malignant pleural mesothelioma? An observational study.Thorac. Cancer202112111752175610.1111/1759‑7714.1398733949775
     [Google Scholar]
  29. Fels ElliottD.R. JonesK.D. Diagnosis of Mesothelioma.Surg. Pathol. Clin.2020131738910.1016/j.path.2019.10.00132005436
     [Google Scholar]
  30. ScagliottiG.V. GaafarR. NowakA.K. NakanoT. van MeerbeeckJ. PopatS. VogelzangN.J. GrossoF. AboelhassanR. JakopovicM. CeresoliG.L. TaylorP. OrlandiF. FennellD.A. NovelloS. ScherpereelA. KuribayashiK. CedresS. SørensenJ.B. PavlakisN. ReckM. VelemaD. von WangenheimU. KimM. BarruecoJ. TsaoA.S. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial.Lancet Respir. Med.20197756958010.1016/S2213‑2600(19)30139‑031103412
     [Google Scholar]
  31. LeshemY. KingE. MazorR. ReiterY. PastanI. Ss1p immunotoxin induces markers of immunogenic cell death and enhances the effect of the ctla-4 blockade in ae17m mouse mesothelioma tumors.Toxins2018101147010.3390/toxins1011047030441807
     [Google Scholar]
  32. CheadleE.J. SheardV. HombachA.A. ChmielewskiM. RietT. BerrevoetsC. SchootenE. LamersC. AbkenH. DebetsR. GilhamD.E. Chimeric antigen receptors for T-cell based therapy.Methods Mol. Biol.201290764566610.1007/978‑1‑61779‑974‑7_3622907378
     [Google Scholar]
  33. HassanR. AlleyE. KindlerH. AntoniaS. JahanT. HonarmandS. NairN. WhitingC.C. EnstromA. LemmensE. TsujikawaT. KumarS. ChoeG. ThomasA. McDougallK. MurphyA.L. JaffeeE. CoussensL.M. BrockstedtD.G. Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (crs-207) with chemotherapy in patients with malignant pleural mesothelioma.Clin. Cancer Res.201925195787579810.1158/1078‑0432.CCR‑19‑007031263030
     [Google Scholar]
  34. ChintalaN.K. RestleD. QuachH. SainiJ. BellisR. OffinM. BeattieJ. AdusumilliP.S. CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.Lung Cancer2021157485910.1016/j.lungcan.2021.05.00433972125
     [Google Scholar]
  35. PeaseD.F. KratzkeR.A. Oncolytic viral therapy for mesothelioma.Front. Oncol.2017717910.3389/fonc.2017.0017928884088
     [Google Scholar]
  36. DansonS.J. ConnerJ. EdwardsJ.G. BlythK.G. FisherP.M. MuthanaM. SalawuA. TaylorF. HodgkinsonE. JoyceP. RomanJ. SimpsonK. GrahamA. LearmonthK. WollP.J. Oncolytic herpesvirus therapy for mesothelioma : A phase I/IIa trial of intrapleural administration of HSV1716.Lung Cancer202015014515110.1016/j.lungcan.2020.10.00733160198
     [Google Scholar]
  37. GrayS.G. MuttiL. Immunotherapy for mesothelioma: A critical review of current clinical trials and future perspectives.Transl. Lung Cancer Res.20209S1Suppl. 1S100S11910.21037/tlcr.2019.11.2332206576
     [Google Scholar]
  38. CornelissenR. LievenseL.A. HeuversM.E. MaatA.P. HendriksR.W. HoogstedenH.C. HegmansJ.P. AertsJ.G. Dendritic cell-based immunotherapy in mesothelioma.Immunotherapy20124101011102210.2217/imt.12.10823148753
     [Google Scholar]
  39. DumoulinD.W. CornelissenR. BezemerK. BaartS.J. AertsJ.G.J.V. Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase i/ii trials.Vaccines20219552510.3390/vaccines905052534069348
     [Google Scholar]
  40. DeianaC. FabbriF. TavolariS. PalloniA. BrandiG. Improvements in systemic therapies for advanced malignant mesothelioma.Int. J. Mol. Sci.202324131041510.3390/ijms24131041537445594
     [Google Scholar]
  41. HassanR. ThomasA. NemunaitisJ.J. PatelM.R. BennounaJ. ChenF.L. DelordJ.P. DowlatiA. KochuparambilS.T. TaylorM.H. PowderlyJ.D. VaishampayanU.N. VerschraegenC. GroteH.J. von HeydebreckA. ChinK. GulleyJ.L. Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: Phase 1b results from the javelin solid tumor trial.JAMA Oncol.20195335135710.1001/jamaoncol.2018.542830605211
     [Google Scholar]
  42. AhmadzadaT. CooperW.A. HolmesM. MaharA. WestmanH. GillA.J. NordmanI. YipP.Y. PalA. ZielinskiR. Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world australian population.JTO Clin Res Rep20201410007510.1016/j.jtocrr.2020.100075
     [Google Scholar]
  43. MaioM. ScherpereelA. CalabròL. AertsJ. PerezS.C. BearzA. NackaertsK. FennellD.A. KowalskiD. TsaoA.S. TaylorP. GrossoF. AntoniaS.J. NowakA.K. TaboadaM. PuglisiM. StockmanP.K. KindlerH.L. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.Lancet Oncol.20171891261127310.1016/S1470‑2045(17)30446‑128729154
     [Google Scholar]
  44. CalabròL. RossiG. MorraA. RosatiC. CutaiaO. DaffinàM.G. AltomonteM. Di GiacomoA.M. CasulaM. FazioC. PalmieriG. GiannarelliD. CovreA. MaioM. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.Lancet Respir. Med.20219996997610.1016/S2213‑2600(21)00043‑633844995
     [Google Scholar]
  45. KrugL.M. PassH.I. RuschV.W. KindlerH.L. SugarbakerD.J. RosenzweigK.E. FloresR. FriedbergJ.S. PistersK. MonbergM. ObasajuC.K. VogelzangN.J. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.J. Clin. Oncol.200927183007301310.1200/JCO.2008.20.394319364962
     [Google Scholar]
  46. RiceD.C. SmytheW.R. LiaoZ. GuerreroT. ChangJ.Y. McAleerM.F. JeterM.D. CorreaA. VaporciyanA.A. LiuH.H. KomakiR. ForsterK.M. StevensC.W. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.Int. J. Radiat. Oncol. Biol. Phys.200769235035710.1016/j.ijrobp.2007.03.01117467922
     [Google Scholar]
  47. ChoB.C.J. DonahoeL. BradburyP.A. LeighlN. KeshavjeeS. HopeA. PalP. CabaneroM. CzarneckaK. McRaeK. TsaoM.S. de PerrotM. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.Lancet Oncol.202122219019710.1016/S1470‑2045(20)30606‑933450184
     [Google Scholar]
  48. ChoB.C.J. FeldR. LeighlN. OpitzI. AnrakuM. TsaoM.S. HwangD.M. HopeA. de PerrotM. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the “SMART” approach for resectable malignant pleural mesothelioma.J. Thorac. Oncol.20149339740210.1097/JTO.000000000000007824445595
     [Google Scholar]
  49. de PerrotM. FeldR. LeighlN.B. HopeA. WaddellT.K. KeshavjeeS. ChoB.C.J. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.J. Thorac. Cardiovasc. Surg.2016151246847510.1016/j.jtcvs.2015.09.12926614413
     [Google Scholar]
  50. RimnerA. ZaudererM.G. GomezD.R. AdusumilliP.S. ParharP.K. WuA.J. WooK.M. ShenR. GinsbergM.S. YorkeE.D. RiceD.C. TsaoA.S. RosenzweigK.E. RuschV.W. KrugL.M. Phase ii study of hemithoracic intensity-modulated pleural radiation therapy (imprint) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma.J. Clin. Oncol.201634232761276810.1200/JCO.2016.67.267527325859
     [Google Scholar]
  51. ZengJ. BadiyanS.N. GarcesY.I. WongT. ZhangX. SimoneC.B.II ChangJ.Y. KnopfA.C. MoriS. IwataH. MeijersA. LiH. BuesM. LiuW. SchildS.E. RenganR. Consensus statement on proton therapy in mesothelioma.Pract. Radiat. Oncol.202111211913310.1016/j.prro.2020.05.00432461036
     [Google Scholar]
  52. RosenzweigK.E. ZaudererM.G. LaserB. KrugL.M. YorkeE. SimaC.S. RimnerA. FloresR. RuschV. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.Int. J. Radiat. Oncol. Biol. Phys.20128341278128310.1016/j.ijrobp.2011.09.02722607910
     [Google Scholar]
  53. FromentM.A. FréchetteÉ. DagnaultA. Prophylactic irradiation of intervention sites in malignant pleural mesothelioma.Radiother. Oncol.2011101230731010.1016/j.radonc.2011.08.03821981876
     [Google Scholar]
  54. NagendranM. PallisA. PatelK. ScarciM. Should all patients who have mesothelioma diagnosed by video-assisted thoracoscopic surgery have their intervention sites irradiated?: Table 1.Interact. Cardiovasc. Thorac. Surg.2011131666910.1510/icvts.2011.26725221451088
     [Google Scholar]
  55. CliveA.O. TaylorH. DobsonL. WilsonP. de WintonE. PanakisN. PepperellJ. HowellT. StewartS.A. PenzE. JordanN. MorleyA.J. Zahan-EvansN. SmithS. BatchelorT.J.P. MarchbankA. BishopL. IonescuA.A. BayneM. CooperS. KerryA. JenkinsP. ToyE. VigneswaranV. GildersleveJ. AhmedM. McDonaldF. ButtonM. LewanskiC. CominsC. DakshinamoorthyM. LeeY.C.G. RahmanN.M. MaskellN.A. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): A multicentre, open-label, phase 3, randomised controlled trial.Lancet Oncol.20161781094110410.1016/S1470‑2045(16)30095‑X27345639
     [Google Scholar]
  56. BaymanN. AppelW. AshcroftL. BaldwinD.R. BatesA. DarlisonL. EdwardsJ.G. EzhilV. GilliganD. HattonM. JegannathenA. MansyT. PeakeM.D. PembertonL. RintoulR.C. SneeM. RyderW.D. TaylorP. Faivre-FinnC. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: An open-label, multicenter, phase iii randomized trial.J. Clin. Oncol.201937141200120810.1200/JCO.18.0167830920878
     [Google Scholar]
  57. HanY. ZhangT. ChenH. YangX. Global magnitude and temporal trend of mesothelioma burden along with the contribution of occupational asbestos exposure in 204 countries and territories from 1990 to 2019: Results from the Global Burden of Disease Study 2019.Crit. Rev. Oncol. Hematol.202217910382110.1016/j.critrevonc.2022.10382136165817
     [Google Scholar]
  58. GregorcV. GaafarR.M. FavarettoA. GrossiF. JassemJ. PolychronisA. BidoliP. TiseoM. ShahR. TaylorP. NovelloS. MuzioA. BearzA. GreillierL. FontanaF. SaliniG. LambiaseA. O’BrienM. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): A randomised, double-blind, placebo-controlled phase 3 trial.Lancet Oncol.201819679981110.1016/S1470‑2045(18)30193‑129753703
     [Google Scholar]
  59. ZaudererM.G. SzlosarekP.W. Le MoulecS. PopatS. TaylorP. PlanchardD. ScherpereelA. KoczywasM. ForsterM. CameronR.B. PeikertT. ArgonE.K. MichaudN.R. SzantoA. YangJ. ChenY. KansraV. AgarwalS. FennellD.A. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study.Lancet Oncol.202223675876710.1016/S1470‑2045(22)00277‑735588752
     [Google Scholar]
  60. KindlerH.L. NovelloS. BearzA. CeresoliG.L. AertsJ.G.J.V. SpicerJ. TaylorP. NackaertsK. GreystokeA. JennensR. CalabròL. BurgersJ.A. SantoroA. CedrésS. SerwatowskiP. PonceS. Van MeerbeeckJ.P. NowakA.K. BlumenscheinG.Jr SiegelJ.M. KastenL. KöchertK. WalterA.O. ChildsB.H. ElbiC. HassanR. FennellD.A. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): A randomised, open-label phase 2 trial.Lancet Oncol.202223454055210.1016/S1470‑2045(22)00061‑435358455
     [Google Scholar]
  61. GhafoorA. MianI. WagnerC. MalloryY. AgraM.G. MorrowB. WeiJ.S. KhanJ. ThomasA. SenguptaM. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline or somatic mutations in bap1 gene.JTO Clin Res Rep202121010023110.1016/j.jtocrr.2021.100231
     [Google Scholar]
  62. NakagawaK. KijimaT. OkadaM. MoriseM. KatoM. HiranoK. FujimotoN. TakenoyamaM. YokouchiH. OheY. Phase 2 study of ys110, a recombinant humanized anti-cd26 monoclonal antibody, in japanese patients with advanced malignant pleural mesothelioma.JTO Clin Res Rep20212610017810.1016/j.jtocrr.2021.100178
     [Google Scholar]
  63. WozniakA.J. SchneiderB. KalemkerianG.P. DalyB. ChenW. VentimigliaJ. NagasakaM. ZaudererM.G. Short report of a phase ii trial of nintedanib in recurrent malignant pleural mesothelioma (mpm).Clin. Lung Cancer202324656356710.1016/j.cllc.2023.04.00437301693
     [Google Scholar]
  64. OuS.H.I. MoonJ. GarlandL.L. MackP.C. TestaJ.R. TsaoA.S. WozniakA.J. GandaraD.R. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).J. Thorac. Oncol.201510238739110.1097/JTO.000000000000036025611229
     [Google Scholar]
  65. GayC.M. ZhouY. LeeJ.J. TangX.M. LuW. WistubaR.II A Phase II trial of alisertib (MLN8237) in salvage malignant mesothelioma.Oncologist20202510e1457e146310.1634/theoncologist.2020‑0610
     [Google Scholar]
  66. JohnsonM.L. ChoB.C. LuftA. Alatorre-AlexanderJ. GeaterS.L. LaktionovK. KimS.W. UrsolG. HusseinM. LimF.L. YangC.T. AraujoL.H. SaitoH. ReinmuthN. ShiX. PooleL. PetersS. GaronE.B. MokT. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase iii poseidon study.J. Clin. Oncol.20234161213122710.1200/JCO.22.0097536327426
     [Google Scholar]
  67. PassigliaF. RighiL. BironzoP. ListìA. FarineaG. CapellettoE. NovelloS. MerliniA. ScagliottiG.V. Niraparib plus dostarlimab in pleural mesothelioma or non-small cell lung cancer harboring hrr mutations: Interim results of the unito-001 phase ii prospective trial.Clin. Cancer Res.202430595996410.1158/1078‑0432.CCR‑23‑243138109438
     [Google Scholar]
  68. TsaoA.S. LinH. CarterB.W. LeeJ.J. RiceD. VaporcyanA. SwisherS. MehranR. HeymachJ. NilssonM. FanY. NunezM. DiaoL. WangJ. FujimotoJ. WistubaI.I. HongW.K. Biomarker-integrated neoadjuvant dasatinib trial in resectable malignant pleural mesothelioma.J. Thorac. Oncol.201813224625710.1016/j.jtho.2017.10.03329313814
     [Google Scholar]
  69. ZaudererM.G. AlleyE.W. BendellJ. CapellettoE. BauerT.M. CalliesS. SzpurkaA.M. KangS. WillardM.D. WacheckV. VargheseA.M. Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.Invest. New Drugs20213941081108810.1007/s10637‑021‑01086‑633660194
     [Google Scholar]
  70. ScherpereelA. MazieresJ. GreillierL. LantuejoulS. DôP. BylickiO. MonnetI. CorreR. Audigier-ValetteC. Locatelli-SanchezM. MolinierO. GuisierF. UrbanT. Ligeza-PoissonC. PlanchardD. AmourE. MorinF. Moro-SibilotD. ZalcmanG. DebieuvreD. HiretS. CadranelJ. Fraboulet-MoreauS. CarmierD. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial.Lancet Oncol.201920223925310.1016/S1470‑2045(18)30765‑430660609
     [Google Scholar]
  71. BelderbosR.A. BaasP. BerardiR. CornelissenR. FennellD.A. van MeerbeeckJ.P. ScherpereelA. VromanH. AertsJ.G.J.V. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.Transl. Lung Cancer Res.20198328028510.21037/tlcr.2019.05.0531367541
     [Google Scholar]
  72. Quispel-JanssenJ. van der NoortV. de VriesJ.F. ZimmermanM. LalezariF. ThunnissenE. MonkhorstK. SchoutenR. SchunselaarL. DisselhorstM. KlompH. HarteminkK. BurgersS. BuikhuisenW. BaasP. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma.J. Thorac. Oncol.201813101569157610.1016/j.jtho.2018.05.03829908324
     [Google Scholar]
  73. ZaudererM.G. TsaoA.S. DaoT. PanageasK. LaiW.V. RimnerA. RuschV.W. AdusumilliP.S. GinsbergM.S. GomezD. RiceD. MehranR. ScheinbergD.A. KrugL.M. A randomized phase ii trial of adjuvant galinpepimut-s, wt-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma.Clin. Cancer Res.201723247483748910.1158/1078‑0432.CCR‑17‑216928972039
     [Google Scholar]
  74. CanovaS. CeresoliG.L. GrossoF. ZucaliP.A. GelsominoF. PaselloG. MencoboniM. RulliE. GalliF. De SimoneI. CarlucciL. De AngelisA. BellettiM. BonomiM. D’AveniA. PerrinoM. BonoF. CortinovisD.L. CortinovisD. CanovaS. ColoneseF. AbbateM.I. SalaL. SalaE. Perez GilaM. BonoF. PagniF. CeresoliG.L. D’AveniA. BonomiM. GrossoF. De AngelisA. UgoF. BellettiM. ZucaliP.A. PerrinoM. De VincenzoF. SantoroA. GelsominoF. ArdizzoniA. PaselloG. FregaS. MencoboniM. CarlucciL. De SimoneI. D’IncalciM. GalliF. PoliD. RulliE. TorriV. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.ESMO Open20227610064410.1016/j.esmoop.2022.10064436463732
     [Google Scholar]
  75. BeattyG.L. HaasA.R. MausM.V. TorigianD.A. SoulenM.C. PlesaG. ChewA. ZhaoY. LevineB.L. AlbeldaS.M. KalosM. JuneC.H. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Cancer Immunol. Res.20142211212010.1158/2326‑6066.CIR‑13‑017024579088
     [Google Scholar]
  76. HaasA.R. TanyiJ.L. O’HaraM.H. GladneyW.L. LaceyS.F. TorigianD.A. SoulenM.C. TianL. McGarveyM. NelsonA.M. FarabaughC.S. MoonE. LevineB.L. MelenhorstJ.J. PlesaG. JuneC.H. AlbeldaS.M. BeattyG.L. Phase i study of lentiviral-transduced chimeric antigen receptor-modified t cells recognizing mesothelin in advanced solid cancers.Mol. Ther.201927111919192910.1016/j.ymthe.2019.07.01531420241
     [Google Scholar]
  77. BaverelP. RoskosL. TatipalliM. LeeN. StockmanP. TaboadaM. ViciniP. HorganK. NarwalR. Exposure-response analysis of overall survival for tremelimumab in unresectable malignant mesothelioma: The confounding effect of disease status.Clin. Transl. Sci.201912545045810.1111/cts.1263330883000
     [Google Scholar]
  78. NishikawaK. TakahashiK. KarjalainenA. WenC.P. FuruyaS. HoshuyamaT. TodorokiM. KiyomotoY. WilsonD. HigashiT. OhtakiM. PanG. WagnerG. Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: A global assessment.Environ. Health Perspect.2008116121675168010.1289/ehp.1127219079719
     [Google Scholar]
  79. LinC.K. ChangY.Y. WangJ.D. LeeL.J. Increased standardised incidence ratio of malignant pleural mesothelioma in taiwanese asbestos workers: A 29-year retrospective cohort study.Biomed Res Int2015201567859810.1155/2015/678598
     [Google Scholar]
  80. KrupovesA. CamusM. De GuireL. Incidence of malignant mesothelioma of the pleura in Québec and Canada from 1984 to 2007, and projections from 2008 to 2032.Am. J. Ind. Med.201558547348210.1002/ajim.2244225754500
     [Google Scholar]
  81. SatoY. TomitaM. SogaT. OchiaiA. MakinoshimaH. Upregulation of thymidylate synthase induces pemetrexed resistance in malignant pleural mesothelioma.Front. Pharmacol.20211271867510.3389/fphar.2021.71867534646134
     [Google Scholar]
  82. BronteG. IncorvaiaL. RizzoS. PassigliaF. GalvanoA. RizzoF. RolfoC. FanaleD. ListìA. NatoliC. BazanV. RussoA. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Crit. Rev. Oncol. Hematol.2016107203210.1016/j.critrevonc.2016.08.01127823648
     [Google Scholar]
  83. CersosimoF. BarbarinoM. LonardiS. VermiW. GiordanoA. BellanC. GiurisatoE. Mesothelioma malignancy and the microenvironment: Molecular mechanisms.Cancers20211322566410.3390/cancers1322566434830817
     [Google Scholar]
  84. Cortes-DericksL. FromentL. BoeschR. SchmidR.A. KaroubiG. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity.BMC Cancer201414130410.1186/1471‑2407‑14‑30424884875
     [Google Scholar]
  85. RobinsonB.W.S. LakeR.A. Advances in malignant mesothelioma.N. Engl. J. Med.2005353151591160310.1056/NEJMra05015216221782
     [Google Scholar]
  86. RobinsonB.M. Malignant pleural mesothelioma: An epidemiological perspective.Ann. Cardiothorac. Surg.20121449149610.3978/j.issn.2225‑319X.2012.11.0423977542
     [Google Scholar]
  87. NagamatsuY. SakyoY. BarrogaE. KoniR. NatoriY. MiyashitaM. Depression and complicated grief, and associated factors, of bereaved family members of patients who died of malignant pleural mesothelioma in japan.J. Clin. Med.20221112338010.3390/jcm1112338035743451
     [Google Scholar]
  88. NagamatsuY. SakyoY. BarrogaE. KoniR. NatoriY. MiyashitaM. Bereaved family members’ perspectives of good death and quality of end-of-life care for malignant pleural mesothelioma patients: A cross-sectional study.J. Clin. Med.2022119254110.3390/jcm1109254135566667
     [Google Scholar]
  89. BorrelliE. BabcockZ. KogutS. Costs of medical care for mesothelioma.Rare Tumors201911203636131986349810.1177/203636131986349831360386
     [Google Scholar]
/content/journals/cctr/10.2174/0115733947315242240718074626
Loading
Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects
Curr Cancer Ther Rev 21, 597 (2025); https://doi.org/10.2174/0115733947315242240718074626
/content/journals/cctr/10.2174/0115733947315242240718074626
/content/journals/cctr/10.2174/0115733947315242240718074626
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): asbestos; carbon nanotubes; immunotherapy; mesothelioma; occupational health; Pleura; socioeconomic burden

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test